Extract
Since 1973 the World Symposia on Pulmonary Hypertension (WSPH) proceedings have summarised the scientific advances and future needs in this field through the efforts of multiple task forces, each focusing on a different aspect of pulmonary hypertension (PH) [1]. The 6th WSPH comprised 124 experts, divided into 13 task forces, that began their work in January 2017 and presented their consensus opinions to an audience of 1376 participant attendees between February 27 and March 1, 2018 in Nice, France. A newly created task force dedicated to patients' perspectives, including representatives of patients' associations worldwide, was added for the 6th WSPH.
Abstract
State of the art summary on diagnosis, prognosis, therapy and future perspectives of pulmonary hypertension http://ow.ly/8MHN30mGtqs
Footnotes
Conflict of interest: N. Galiè reports grants and personal fees from Actelion, Bayer, GSK and Pfizer, and personal fees from MSD, outside the submitted work.
Conflict of interest: V.V. McLaughlin reports grants and personal fees from Actelion, Acceleron, Arena and Bayer, personal fees from Caremark and United Therapeutics, and grants from Gilead and Sonovie, during the conduct of the study.
Conflict of interest: L. Rubin reports personal fees from Actelion, Arena, Bellerophon, SoniVie and Roivant, during the conduct of the study.
Conflict of interest: G. Simonneau reports grants, personal fees and non-financial support from Actelion Pharmaceuticals, Bayer Healthcare, Merck and GlaxoSmithKline.
- Received November 10, 2018.
- Accepted November 13, 2018.
- Copyright ©ERS 2019
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.